Considerations for Support

Educational grants are funded in a manner that preserves the independence of educational programs from commercial influence and complies with applicable federal and state laws and regulations, accrediting body guidelines for medical education, relevant industry codes, and the CSL Behring US policy on Educational Grants.

Decisions made by CSL Behring with respect to Grant requests are not connected with or conditioned upon past, present, or future prescribing, referring, recommending, contracting, determination of formulary status, and/or utilization of any CSL Behring product.

Educational Grants are issued in support of programs that include, but are not limited to, medical seminars and symposia, grand rounds, sessions at physician specialty meetings and conventions, and programs for which continuing medical education credits are approved.

We specifically focus on these therapeutic areas:

  • Coagulation
    • Programs that increase understanding and medical expertise in the field of coagulation.
    • Programs that expand awareness of the challenges that patients with hemophilia face and the role of innovations in hemophilia treatment.
  • Primary Immunodeficiency Disorders (PIDD)
    • Programs that raise awareness of disease burden and expand diagnosis, such as those focused on newborn screening initiatives or among adults with comorbidities (e.g., chronic lung disease, autoimmune diseases).
    • Programs that expand knowledge of the therapeutic strategies for management of antibody deficiencies using immunoglobulin replacement via intravenous and subcutaneous routes and/or efficacy and safety in special populations.
  • Neuromuscular disorders, especially Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) consistent with Clinical Development
    • Programs that improve diagnostic accuracy and awareness of appropriate assessment criteria.
    • Programs that foster knowledge of appropriate management and assessment of patient outcomes.
  • Acquired Bleeding
    • Programs designed to educate in areas including: warfarin reversal (administration/dosing, acute care surgery, ICH and neurocritical care), treatment of novel oral anticoagulant (NOAC)-associated bleeding, trauma/pre-hospital care, GI bleeding and transfusion medicine/blood management.
  • Hereditary Angioedema (HAE)
    • Programs that enhance the knowledge of the diagnosis, prevention and treatment of hereditary angioedema types I & II, and hereditary angioedema with normal C1-INH.
    • Programs that raise awareness around the appropriate HAE medication use/administration.
  • Alpha-1 Antitrypsin Deficiency (AATD)
    • Programs that enhance the knowledge around identifying the natural course of emphysema-related AATD and diagnosis.
    • Programs that address the burden of disease and explore the effect and safety of AATD therapies.
Our Request Requirements have recently changed. Please take a moment to review them.